by Darshana Jani, Kaz Reynhardt, Michael Quinn, Bibrama Sinha, and Meena Subramanyam
Volume 7, Issue 4 (Winter 2008)
The recombinant protein alefacept (Amevive®) is an immunomodulator approved for the treatment of moderate to severe chronic plaque psoriasis. In phase 3 clinical studies, treatment of psoriatic patients with alefacept at a safe and well-tolerated dose caused meaningful reductions in psoriasis area and severity index and in physician global assessment scores as well…
Citation:
Jani D, Reynhardt K, Quinn M, Sinha B, Subramanyam M. Development and Validation of a Calcium Mobilization Assay for the Detection of Neutralizing Antibodies to Alefacept in Human Serum. BioProcess J, 2008; 7(4): 8-18. http://dx.doi.org/10.12665/J74.Jani